TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 81 filers reported holding TCR2 THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $140,900 | +63.1% | 93,933 | +8.6% | 0.00% | – |
| Q4 2022 | $86,388 | -46.3% | 86,492 | -3.7% | 0.00% | – |
| Q3 2022 | $161,000 | -35.3% | 89,813 | +4.5% | 0.00% | – |
| Q2 2022 | $249,000 | -68.6% | 85,937 | -70.1% | 0.00% | – |
| Q1 2022 | $793,000 | -45.8% | 287,251 | -8.6% | 0.00% | – |
| Q4 2021 | $1,464,000 | -47.0% | 314,171 | -3.1% | 0.00% | – |
| Q3 2021 | $2,760,000 | -49.2% | 324,310 | -2.1% | 0.00% | -100.0% |
| Q2 2021 | $5,435,000 | -25.3% | 331,163 | +0.5% | 0.00% | 0.0% |
| Q1 2021 | $7,274,000 | -30.1% | 329,425 | -2.1% | 0.00% | -50.0% |
| Q4 2020 | $10,404,000 | +49.2% | 336,390 | -2.0% | 0.00% | 0.0% |
| Q3 2020 | $6,975,000 | +78.1% | 343,287 | +34.6% | 0.00% | +100.0% |
| Q2 2020 | $3,917,000 | +228.9% | 255,004 | +65.7% | 0.00% | – |
| Q1 2020 | $1,191,000 | -43.5% | 153,853 | +4.2% | 0.00% | – |
| Q4 2019 | $2,107,000 | 0.0% | 147,581 | +5.3% | 0.00% | -100.0% |
| Q3 2019 | $2,107,000 | – | 140,171 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
| MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
| Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
| Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
| Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
| PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
| Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
| MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
| Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |